Research and development cost share contract to develop exebacase.
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50121C00021
- Awardee
-
Contrafect Corporation UEI LXUZL23QTTZ9
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $16,381,940
Award facts
- Opportunity
-
- R & D to develop Execabase to combat S. aureus Award Notice · Posted Mar 11, 2021
- Contract value 100% obligated
- $16,381,940.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
- Place of performance
- Yonkers, NY 10701, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $6,614,714 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Original award | $9,767,226 |
About this award
This is a $16,381,940.00 cost-sharing research and development contract awarded by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Contrafect Corporation, a self-certified small disadvantaged business and for-profit organization. The contract is for the development of Exebacase, a direct lytic agent to combat Staphylococcus aureus. The contract work will be performed in Yonkers, New York and is expected to conclude in July 2023. This contract is not set aside. Contrafect Corporation has previously received prime federal contracts and grants, as well as subcontract awards, for the research and development of novel antimicrobial therapies using recombinant lysin proteins.
Quick answers
Who was awarded contract 75A50121C00021?
75A50121C00021 was awarded to Contrafect Corporation by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on March 15, 2021.
How much is contract 75A50121C00021 worth?
The government has obligated $16,381,940 on 75A50121C00021.
Was contract 75A50121C00021 competed?
The extent of competition for 75A50121C00021 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award